HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Miller, Kathy, Cortes, Javier, Hurvitz, Sara A., Krop, Ian E., Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G., Wickham, Thomas J., Molnar, Istvan, Yardley, Denise A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893300/
https://ncbi.nlm.nih.gov/pubmed/27259714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2385-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados